Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Medullary thyroid cancer, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No cure once the disease has spread beyond the neck.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Resistance mutations to RET inhibitors (G810) are emerging.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
RET-negative sporadic disease has no targeted option.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 15 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Accelerated approval, RET-fusion NSCLC and thyroid cancer, RET-mutant MTC (LIBRETTO-001)
RET-fusion NSCLC and thyroid; RET-mutant MTC
A milestone in how this cancer is treated.
Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016